CELL INTELLIGENCE · 肿瘤细胞治疗研究
肿瘤细胞治疗研究
英文原题:Histopathologic clues to mismatch repair deficiency in colon adenocarcinoma: the role of mucinous component and intratumoral/Crohn-like immune response.
Histopathologic clues to mismatch repair deficiency in colon adenocarcinoma: the role of mucinous component and intratumoral/Crohn-like immune response.
分数与星级只用于站内排序 —— 不代表疗效、安全性或个人适用性。
伴有黏液成分和瘤内/Crohn 样免疫反应的结肠腺癌中 dMMR 富集,而缺乏这两种特征的肿瘤 dMMR 发生率低。这些发现提供了 dMMR 富集表型的详细组织病理学特征,但不应被用于选择 MMR 检测病例或替代普遍检测。
错配修复缺陷(dMMR)是结肠腺癌中一个生物学上独特的亚型,具有重要的诊断、遗传、预后和治疗意义。本研究探讨了黏液成分和免疫反应模式是否可作为常规病理实践中dMMR的实用组织病理学线索。
这项回顾性研究纳入了2022年至2025年间连续222例结肠腺癌切除病例,这些病例均有可用的错配修复(MMR)免疫组化结果。根据MMR状态对临床病理、组织形态学和免疫反应特征进行了评估和比较。采用多变量logistic回归分析以确定与dMMR独立相关的因素。
在222个肿瘤中,29个(13.1%)为dMMR,193个(86.9%)为MMR正常。dMMR与年龄<50岁(40.9% vs. 10.0%,p < 0.001)、高级别(25.8% vs. 8.5%,p = 0.010)、无淋巴结转移(18.8% vs. 6.7%,p = 0.007)、无神经周围侵犯(21.6% vs. 6.4%,p = 0.001)、较大的肿瘤体积(p < 0.001)、较少的转移淋巴结(p = 0.038)以及较高的淋巴结检出数(p = 0.019)显著相关。肿瘤内/Crohn样免疫反应与dMMR强烈相关(33.9% vs. 6.1%,p < 0.001)。伴有黏液成分的肿瘤dMMR率高于无黏液成分者(26.2% vs. 10.0%,p = 0.005)。在未校正分析中所有显著的关联经错误发现率校正后仍保持显著(q < 0.05)。在联合组织病理学线索分析中,dMMR率从无线索肿瘤的2.3%升高至有一条线索的28.2%和两条线索均有的40.0%。在多变量分析中,年龄<50岁(OR 7.212,p = 0.002)、肿瘤内/Crohn样免疫反应(OR 7.089,p < 0.001)和黏液成分(OR 6.067,p = 0.001)仍与dMMR独立相关。
Deficient mismatch repair (dMMR) identifies a biologically distinct subset of colon adenocarcinomas with important diagnostic, hereditary, prognostic, and therapeutic implications. This study investigated whether mucinous component and immune response pattern may serve as practical histopathologic clues to dMMR in routine pathology practice.
This retrospective study included 222 consecutive colon adenocarcinoma resection cases with available mismatch repair (MMR) immunohistochemistry from 2022 to 2025. Clinicopathologic, histomorphologic, and immune response features were evaluated and compared according to MMR status. Multivariable logistic regression was performed to identify factors independently associated with dMMR.
Of 222 tumors, 29 (13.1%) were dMMR and 193 (86.9%) were proficient MMR. dMMR was significantly associated with age < 50 years (40.9% vs. 10.0%, p < 0.001), high grade (25.8% vs. 8.5%, p = 0.010), absence of lymph node metastasis (18.8% vs. 6.7%, p = 0.007), absence of perineural invasion (21.6% vs. 6.4%, p = 0.001), larger tumor size (p < 0.001), fewer metastatic lymph nodes (p = 0.038), and higher lymph node yield (p = 0.019). Intratumoral/Crohn-like immune response was strongly associated with dMMR (33.9% vs. 6.1%, p < 0.001). Tumors with a mucinous component showed a higher dMMR rate than those without (26.2% vs. 10.0%, p = 0.005). All associations that were significant in the unadjusted analyses remained significant after false discovery rate correction (q < 0.05). In the combined histopathologic clue analysis, the dMMR rate increased from 2.3% in tumors with no clue to 28.2% with one clue and 40.0% with both clues. In multivariable analysis, age < 50 years (OR 7.212, p = 0.002), intratumoral/Crohn-like immune response (OR 7.089, p < 0.001), and mucinous component (OR 6.067, p = 0.001) remained independently associated with dMMR.
Colon adenocarcinomas with a mucinous component and an intratumoral/Crohn-like immune response are enriched for dMMR, whereas tumors lacking both features show a low dMMR rate. These findings provide a detailed histopathologic characterization of a dMMR-enriched phenotype but should not be used to select cases for MMR testing or replace universal testing.
在 PubMed 查看 → 出版商原文(DOI) 全文 PDF(PMC)· 可下载 治疗专题与资料阅读指南 资料来源与翻译说明 报告译文或资料问题 →
MEMBER ACCOUNT
登录成功会直接打开下一页。